Jade Biosciences, Inc. financial data

Symbol
JBIO on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 06 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1351% % 98%
Debt-to-equity 10% % -98%
Return On Equity -81% % 92%
Return On Assets -60% % 18%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49,316,287 shares 70%
Common Stock, Shares, Outstanding 49,316,287 shares 1243%
Entity Public Float $289,400,000 USD 1158%
Common Stock, Value, Issued $5,000 USD 400%
Weighted Average Number of Shares Outstanding, Basic 31,359,958 shares 9.7%
Weighted Average Number of Shares Outstanding, Diluted 31,359,958 shares 9.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $22,010,000 USD 62%
General and Administrative Expense $20,421,000 USD -4.6%
Operating Income (Loss) $113,542,000 USD -52%
Nonoperating Income (Expense) $13,810,000 USD -375%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $127,410,000 USD -83%
Earnings Per Share, Basic -3.19 USD/shares -31%
Earnings Per Share, Diluted -3.19 USD/shares -31%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $88,438,000 USD 27%
Cash, Cash Equivalents, and Short-term Investments $76,200,000 USD -23%
Assets, Current $348,816,000 USD 401%
Property, Plant and Equipment, Net $170,000 USD
Operating Lease, Right-of-Use Asset $726,000 USD
Other Assets, Noncurrent $69,000 USD -98%
Assets $349,781,000 USD 380%
Accounts Payable, Current $2,151,000 USD 67%
Employee-related Liabilities, Current $4,729,000 USD 488%
Accrued Liabilities, Current $9,419,000 USD 128%
Liabilities, Current $16,539,000 USD 38%
Operating Lease, Liability, Noncurrent $724,000 USD
Liabilities $17,263,000 USD -86%
Accumulated Other Comprehensive Income (Loss), Net of Tax $129,000 USD
Retained Earnings (Accumulated Deficit) $174,389,000 USD -271%
Stockholders' Equity Attributable to Parent $332,518,000 USD
Liabilities and Equity $349,781,000 USD 380%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $49,904,000 USD 90%
Net Cash Provided by (Used in) Financing Activities $25,427,000 USD
Net Cash Provided by (Used in) Investing Activities $60,046,000 USD 45%
Common Stock, Shares Authorized 300,000,000 shares 650%
Common Stock, Shares, Issued 49,316,287 shares 1243%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $35,098,000 USD
Deferred Tax Assets, Valuation Allowance $49,571,000 USD 556%
Deferred Tax Assets, Gross $49,969,000 USD 561%
Operating Lease, Liability $851,000 USD 104%
Depreciation $4,000 USD -86%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $127,281,000 USD -82%
Lessee, Operating Lease, Liability, to be Paid $1,116,000 USD 160%
Operating Lease, Liability, Current $312,000 USD -30%
Lessee, Operating Lease, Liability, to be Paid, Year Two $231,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $226,000 USD -47%
Operating Lease, Weighted Average Discount Rate, Percent 0.064 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $265,000 USD 2108%
Lessee, Operating Lease, Liability, to be Paid, Year Three $236,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $11,560,000 USD 2475%
Preferred Stock, Shares Issued 12,622 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $240,000 USD
Operating Lease, Payments $108,000 USD -15%
Additional Paid in Capital $506,771,000 USD
Preferred Stock, Shares Outstanding 12,622 shares
Deferred Tax Assets, Net of Valuation Allowance $398,000 USD 826%
Share-based Payment Arrangement, Expense $20,009,000 USD 77%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%